

Figure S1 IL-35 mostly derived from Regulatory T cells in PH mice. (A) Gating strategy for Tregs collected from Foxp3^{EGFP} mice spleen were defined as CD45+CD3+CD4+CD25+Foxp3+. (B) Experimental protocol for mice receiving Tregs adoptive transference and weekly administration of IL35 inhibition (100 μg first dose, 50 μg additional doses). PH, pulmonary hypertension.

http://dx.doi.org/10.21037/atm-21-1952



Figure S2 IL-35 abrogates pulmonary EC proliferation through STAT1. (A) Experimental protocol for mice receiving ReIL-35 administration every other day and fludarabine as indicated. (B) Effect of ReIL-35 administration along with both ReIL-35 and fludarabine treatment on right ventricular systolic pressure (RVSP) of HySu-induced mice. *P<0.05 *vs.* vehicle group; #P<0.05 *vs.* vehicle group; n=6 per group. (C) RV/(LV+S) weight ratio in HySu-exposed PH mice with ReIL-35 administration without ReIL-35 administration and with both ReIL-35 and STAT1 inhibition administrated. *P<0.05 *vs.* vehicle group; #P<0.05 *vs.* vehicle group; n=6 per group. (D) Representative images of H&E staining of lung sections from HySu-induced mice with ReIL-35 administration, without ReIL-35 administration, and with both ReIL-35 and STAT1 inhibition administrated. Scale bar: 20 μm. EC, endothelial cell. HySu, hypoxia plus SU5416. ReIL-35, recombinant IL-35.

http://dx.doi.org/10.21037/atm-21-1952